Merck has announced that its trial for the drug Sacituzumab Tirumotecan (Sac-TMT) has successfully met primary endpoints in the treatment of advanced or recurrent endometrial cancer, specifically demonstrating improvements in overall survival (OS) and progression-free survival (PFS) among certain patients. This marks a significant advancement for Merck and its innovative antibody-drug conjugate (ADC), which has shown effectiveness in late-stage trials aimed at addressing unmet medical needs in this difficult-to-treat cancer. The positive outcome of the TroFuse-005 trial underscores Merck’s commitment to enhancing treatment options for patients with uterine cancer, including those with treatment-resistant forms of the disease.